As per MRFR analysis, the Glucagon Delivery Device Market Size was estimated at 0.85 (USD Billion) in 2022. The Glucagon Delivery Device Market Industry is expected to grow from 1.01(USD Billion) in 2023 to 4.9 (USD Billion) by 2032. The Glucagon Delivery Device Market CAGR (growth rate) is expected to be around 19.19% during the forecast period (2024-2032).
The increasing burden of diabetes, along with the unmet need for appropriate glucagon delivery methods in hypoglycemic patients, is propelling the growth of the Glucagon Delivery Device Market. Key market drivers are increasing consciousness regarding diabetes management, increasing demand for innovative delivery devices and governmental policies regarding the proper distribution of glucagon.
Over the years, New Glucagon Delivery Devices, which are easy, cheap and accurate, have had a lot of promise. Recent trends show a movement to more wearable and disposable devices, as well as the incorporation of technologically advanced features such as smartphone links and real-time monitoring. The recent boom in telemedicine and remote patient monitoring services is also expected to support the growth of the market.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Diabetes is a chronic metabolic disorder characterized by elevated blood sugar levels. Glucagon is a hormone that helps regulate blood sugar levels by stimulating the liver to release glucose. As the prevalence of diabetes continues to rise ly, so does the demand for glucagon-delivery devices. These devices provide a convenient and effective way to administer glucagon in emergencies, such as when a person with diabetes experiences severe hypoglycemia (low blood sugar).According to the International Diabetes Federation, there were an estimated 537 million adults (20-79 years) living with diabetes in 2021, and this number is projected to reach 643 million by 2030 and 783 million by 2045. The increasing prevalence of diabetes is a major driver of growth in the Glucagon Delivery Device Market Industry.
Technological advancements are also playing a significant role in the growth of the Glucagon Delivery Device Market Industry. The development of new and improved glucagon delivery devices has made it easier and more convenient for people with diabetes to administer glucagon in emergencies. For example, some newer devices are designed to be more compact and portable, making them easier to carry around. Others are designed to be more user-friendly, with features such as pre-filled cartridges and automated dosing.
Government initiatives are also supporting the growth of the Glucagon Delivery Device Market Industry. Many governments are implementing policies and programs to improve access to diabetes care and education. These initiatives are helping to raise awareness of glucagon delivery devices and their benefits, which is leading to increased demand for these devices. For example, in the United States, the Centers for Disease Control and Prevention (CDC) has launched a number of initiatives to improve diabetes care, including the National Diabetes Prevention Program and the National Diabetes Education Program.
Device Type segments the Glucagon Delivery Device Market into Injectable Glucagon, Nasal Glucagon, and Oral Glucagon. The Injectable Glucagon segment held the largest share of the market in 2023 and is expected to continue to dominate the market throughout the forecast period. The growth of this segment can be attributed to the widespread adoption of injectable glucagon products, such as Eli Lilly's glucagon emergency kit, due to their ease of use and effectiveness in treating severe hypoglycemia. The Nasal Glucagon segment is expected to witness significant growth over the forecast period.The growth of this segment can be attributed to the increasing prevalence of diabetes and the growing preference for non-invasive delivery methods. Nasal glucagon products, such as Xeris Pharmaceuticals' Gvoke HypoPen, offer a convenient and discreet way to administer glucagon, making them ideal for patients who are unable or unwilling to use injectable products. The Oral Glucagon segment is expected to experience modest growth over the forecast period. The growth of this segment can be attributed to the development of new oral glucagon products, such as Zealand Pharma's dasiglucagon, which offers a longer-lasting effect than injectable or nasal glucagon products.Oral glucagon products are expected to gain traction in the future as they provide a more convenient and effective way to manage hypoglycemia. Overall, the Glucagon Delivery Device Market is expected to experience significant growth over the forecast period. The growth of the market can be attributed to the increasing prevalence of diabetes, the growing preference for non-invasive delivery methods, and the development of new and innovative glucagon delivery devices.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
The Glucagon Delivery Device Market segmentation by indication includes Severe Hypoglycemia, Type 1 Diabetes, and Type 2 Diabetes. Among these, the Type 1 Diabetes segment held the largest market share of around 60% in 2023 and is expected to continue dominating the market throughout the forecast period. The high prevalence of Type 1 Diabetes, coupled with the increasing adoption of glucagon-delivery devices for its management, is driving the growth of this segment. Moreover, the rising awareness about the benefits of glucagon delivery devices in managing severe hypoglycemia in patients with Type 1 Diabetes is further contributing to the segment's growth.The Type 2 Diabetes segment is also expected to witness significant growth during the forecast period due to the growing prevalence of Type 2 Diabetes and the increasing use of glucagon-delivery devices for its management.
The Glucagon Delivery Device Market is segmented into various end users, including adults and the pediatric population. The adult segment accounted for a larger share of the market in 2023 and is expected to continue to dominate throughout the forecast period. The growth of this segment can be attributed to the increasing prevalence of diabetes among adults, leading to a greater demand for glucagon-delivery devices. The pediatric population segment is also expected to experience significant growth during the forecast period. The rising incidence of diabetes in children and adolescents is driving the demand for glucagon-delivery devices in this segment.Additionally, increasing awareness about the benefits of early intervention and management of diabetes in children is contributing to the growth of this segment.
The reimbursement landscape for glucagon delivery devices varies across different regions and healthcare systems. In the United States, commercial insurance is the primary payer for glucagon delivery devices, covering a significant portion of the market. Medicare and Medicaid also play a role in reimbursement, particularly for individuals with diabetes who qualify for these government-sponsored programs. The availability of reimbursement coverage can impact patient access to glucagon delivery devices, with adequate reimbursement policies supporting increased adoption and usage of these devices.
The regional landscape of the Glucagon Delivery Device Market presents a diverse landscape with varying dynamics across key regions. North America is projected to dominate the market, accounting for a significant share due to the high prevalence of diabetes and the presence of well-established healthcare infrastructure. Europe follows closely, driven by increasing awareness and advancements in diabetes management. The APAC region is anticipated to witness substantial growth, fueled by the rising incidence of diabetes and expanding healthcare access in developing countries.South America and MEA hold promising growth potential, driven by government initiatives and increasing investments in healthcare infrastructure.
Source: Primary Research, Secondary Research, MRFR Database and Analyst Review
Major players in the Glucagon Delivery Device Market industry are constantly striving to gain a competitive edge by focusing on product innovation and expanding their market presence. Leading Glucagon Delivery Device Market players are investing heavily in research and development to create advanced products that meet the evolving needs of patients and healthcare professionals. Glucagon Delivery Device Market development is driven by the increasing prevalence of diabetes and the growing demand for convenient and effective glucose management solutions. The competitive landscape is characterized by a mix of established players and emerging start-ups, all vying for market share through strategic partnerships, acquisitions, and product launches.One of the leading companies in the Glucagon Delivery Device Market is Xeris Pharmaceuticals, Inc. The company's flagship product, Gvoke, is a pre-filled auto-injector that delivers glucagon in a single-dose format.
Gvoke has gained significant market share due to its ease of use, reliability, and proven efficacy in treating severe hypoglycemia. Xeris Pharmaceuticals, Inc. has also expanded its portfolio through acquisitions, such as the purchase of Pearl Therapeutics, Inc. in 2021, which added the SymlinPen device to its product line.A major competitor in the Glucagon Delivery Device Market is Eli Lilly and Company. The company's product, Glucagon Emergency Kit, is a pre-mixed solution of glucagon that requires reconstitution before use. Eli Lilly and Company has a strong presence in the market due to its established brand reputation and extensive distribution network. The company is also actively involved in research and development, with a focus on developing next-generation glucagon delivery devices that offer improved convenience and efficacy.
The glucagon delivery device market is anticipated to witness significant growth over the forecast period from 2024 to 2032. The market is driven by the rising prevalence of diabetes and the increasing adoption of glucagon-delivery devices for the treatment of severe hypoglycemia. Technological advancements and the introduction of new and improved devices are further contributing to the market growth. Key players in the market are focusing on product innovation and strategic partnerships to expand their market share. Recent developments include the launch of new devices with enhanced features, such as faster delivery and improved patient convenience. Strategic partnerships and collaborations are also shaping the market landscape, with companies seeking to combine their expertise and resources to develop and commercialize novel glucagon delivery solutions.
| Report Attribute/Metric | Details |
| Market Size 2022 | 0.85(USD Billion) |
| Market Size 2023 | 1.01(USD Billion) |
| Market Size 2032 | 4.9(USD Billion) |
| Compound Annual Growth Rate (CAGR) | 19.19% (2024 - 2032) |
| Report Coverage | Revenue Forecast, Competitive Landscape, Growth Factors, and Trends |
| Base Year | 2023 |
| Market Forecast Period | 2024 - 2032 |
| Historical Data | 2019 - 2022 |
| Market Forecast Units | USD Billion |
| Key Companies Profiled | BD, Tandem Diabetes Care, Ypsomed, Nipro Corporation, Zealand Pharma A/S, Valeritas, Pharmacia Upjohn, Medtronic, Terumo Corporation, Roche Diabetes Care, Xeris Pharmaceuticals, Inc., Insulet Corporation, Eli Lilly and Company, Novo Nordisk, Abbott Laboratories |
| Segments Covered | Device Type, Indication, End User, Reimbursement, Regional |
| Key Market Opportunities | Rising Prevalence of Diabetes Technological Advancements Increasing Healthcare Expenditure |
| Key Market Dynamics | Rising prevalence of diabetes Expanding applications in emergency settings Technological advancements Increasing demand for noninvasive devices Growing awareness of hypoglycemia. |
| Countries Covered | North America, Europe, APAC, South America, MEA |
Frequently Asked Questions (FAQ) :
The Glucagon Delivery Device Market is expected to reach USD 4.9 billion by 2032, exhibiting a CAGR of 19.19% during the forecast period (2024-2032).
North America is expected to dominate the Glucagon Delivery Device Market, accounting for the largest market share due to the high prevalence of diabetes and the increasing adoption of advanced technologies.
The rising prevalence of diabetes, the growing awareness of glucagon delivery devices, and the technological advancements in these devices are the primary factors driving the market growth.
Glucagon Delivery Devices are primarily used for the treatment of severe hypoglycemia, a condition characterized by dangerously low blood sugar levels.
Novo Nordisk, Eli Lilly and Company, Xeris Pharmaceuticals, and Zealand Pharma are among the leading players in the Glucagon Delivery Device Market.
Emerging economies, such as China and India, present significant growth potential for the Glucagon Delivery Device Market due to the increasing prevalence of diabetes and the growing healthcare infrastructure.
The competitive landscape is expected to intensify with the entry of new players and the development of innovative products, leading to increased competition and consolidation.
The miniaturization of devices, the integration of advanced technologies, and the increasing focus on patient-centric solutions are the key trends shaping the Glucagon Delivery Device Market.
There is a need for more user-friendly devices, improved accuracy and reliability, and the development of devices that can deliver glucagon in different forms.
Glucagon Delivery Devices are subject to regulatory approvals and guidelines to ensure their safety and efficacy.
Leading companies partner with us for data-driven Insights.
Kindly complete the form below to receive a free sample of this Report
Research Analyst Level I He is an extremely curious individual currently working in healthcare and medical devices domain. kinjoll is comfortably versed in data centric research backed by healthcare educational background. he leverages extensive data mining and analytics tools such as primary and secondary research, statistical analysis, machine learning, data modelling. his key role also involves technical sales support, client interaction and project management within the healthcare team. lastly, he showcases extensive affinity towards learning new skills and remain fascinated in implementing them.
Get in Touch
© 2024 Market Research Future ® (Part of WantStats Reasearch And Media Pvt. Ltd.)
